search
Back to results

Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease

Primary Purpose

Arterial Occlusive Diseases

Status
Unknown status
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
Balloon Angioplasty
ReoPro
Sponsored by
University Hospital Tuebingen
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Arterial Occlusive Diseases focused on measuring peripheral vascular disease, intervention, restenosis, Age above 18 years

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with a history of peripheral artery disease with superficial femoral or popliteal artery occlusion, which mandates PTA or stent administration as first treatment modality. The history of peripheral artery occlusion has to be at least 6 weeks, and the target vessel occlusion has to be more than 5 centimeters in length. Age between 18 and 90 years Exclusion Criteria: Acute limb ischemia Subacute ischemia with requires thrombolysis as first treatment modality Active bleeding or known bleeding diathesis Known severe hepatic or renal disorder (liver cirrhosis, stage B, C or serum creatinine > 2.5 mg%) Hyperthyreosis Diabetes mellitus treated with metformin Known heparin induced thrombocytopenia (HIT, type 2) Female sex with childbearing potential Major surgery or trauma in past 6 weeks History of stroke within the previous 2 years, or any stroke with a residual neurological deficit, or other CNS abnormality (e.g., intracranial neoplasm, arteriovenous malformation, or aneurysm) Gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks Administration of oral anticoagulants within the previous 7 days unless prothrombin time is < 1.2 times control (or international normalized ratio [INR] <1.4), or ongoing treatment with oral anticoagulants History of bleeding diathesis of platelet count < 100,000/mm3 Arteriovenous malformations or aneurysms Severe uncontrolled hypertension (treated sys. BP > 200 mm Hg, diast. BP > 100 mm Hg) Hypertensive or diabetic retinopathy Vasculitis Known autoimmune disorders Patient with aspirin intolerance Contraindication or known allergic reactions to abciximab or murine proteins Co-existent condition associated with a limited life expectancy (e.g., advanced cancer, end-stage congestive heart failure) Participation in another clinical research study involving the evaluation of another investigational drug or device within 7 days prior to enrollment Patient who has previously received a GP IIb/IIIa antagonist

Sites / Locations

  • University of Tuebingen

Outcomes

Primary Outcome Measures

Prevention of subacute occlusions within 30 days

Secondary Outcome Measures

Prevention of restenosis up to 3 years
Prevention of target lesion revascularization
Improvement of the clinical status
Change of ABI
Hospital days
all secondary outcomes at 30 days, 6 months, one year, and 3 years (telephone contact after 3 years)

Full Information

First Posted
September 7, 2005
Last Updated
September 11, 2006
Sponsor
University Hospital Tuebingen
Collaborators
University of Bern
search

1. Study Identification

Unique Protocol Identification Number
NCT00156611
Brief Title
Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease
Official Title
ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease - A Randomized Prospective Trial (RIO-Trial)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2006
Overall Recruitment Status
Unknown status
Study Start Date
January 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2009 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
University Hospital Tuebingen
Collaborators
University of Bern

4. Oversight

5. Study Description

Brief Summary
The Rio Study is a randomized, double blinded German- Swiss- Austria multi-centre trial on the efficacy and safety of ReoPro together with interventional recanalization of TASC D lesions in the SFA and popliteal artery.
Detailed Description
Purpose: The RIO trial is designed to test the efficacy of GP IIb/IIIa blockade on subacute reocclusions in patients with interventional recanalization of chronic occlusions in the superficial femoral and popliteal artery. Methods: A total of 420 patients will be randomly assigned to ReoPro or placebo. Patients will be eligible for randomisation with occlusions longer than 5 cm. Doppler ultrasound follow-up will be at 30 days, and after 6, and 12 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arterial Occlusive Diseases
Keywords
peripheral vascular disease, intervention, restenosis, Age above 18 years

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
420 (false)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Balloon Angioplasty
Intervention Type
Drug
Intervention Name(s)
ReoPro
Primary Outcome Measure Information:
Title
Prevention of subacute occlusions within 30 days
Secondary Outcome Measure Information:
Title
Prevention of restenosis up to 3 years
Title
Prevention of target lesion revascularization
Title
Improvement of the clinical status
Title
Change of ABI
Title
Hospital days
Title
all secondary outcomes at 30 days, 6 months, one year, and 3 years (telephone contact after 3 years)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a history of peripheral artery disease with superficial femoral or popliteal artery occlusion, which mandates PTA or stent administration as first treatment modality. The history of peripheral artery occlusion has to be at least 6 weeks, and the target vessel occlusion has to be more than 5 centimeters in length. Age between 18 and 90 years Exclusion Criteria: Acute limb ischemia Subacute ischemia with requires thrombolysis as first treatment modality Active bleeding or known bleeding diathesis Known severe hepatic or renal disorder (liver cirrhosis, stage B, C or serum creatinine > 2.5 mg%) Hyperthyreosis Diabetes mellitus treated with metformin Known heparin induced thrombocytopenia (HIT, type 2) Female sex with childbearing potential Major surgery or trauma in past 6 weeks History of stroke within the previous 2 years, or any stroke with a residual neurological deficit, or other CNS abnormality (e.g., intracranial neoplasm, arteriovenous malformation, or aneurysm) Gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks Administration of oral anticoagulants within the previous 7 days unless prothrombin time is < 1.2 times control (or international normalized ratio [INR] <1.4), or ongoing treatment with oral anticoagulants History of bleeding diathesis of platelet count < 100,000/mm3 Arteriovenous malformations or aneurysms Severe uncontrolled hypertension (treated sys. BP > 200 mm Hg, diast. BP > 100 mm Hg) Hypertensive or diabetic retinopathy Vasculitis Known autoimmune disorders Patient with aspirin intolerance Contraindication or known allergic reactions to abciximab or murine proteins Co-existent condition associated with a limited life expectancy (e.g., advanced cancer, end-stage congestive heart failure) Participation in another clinical research study involving the evaluation of another investigational drug or device within 7 days prior to enrollment Patient who has previously received a GP IIb/IIIa antagonist
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gunnar Tepe, MD
Organizational Affiliation
University Hospital of Tuebingen
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Iris Baumgartner, MD
Organizational Affiliation
University of Bern
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Tuebingen
City
Tuebingen
ZIP/Postal Code
72076
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Rio Trial - ReoPro and Peripheral Arterial Intervention to Improve Clinical Outcome in Patients With Peripheral Arterial Disease

We'll reach out to this number within 24 hrs